Mazdutide
A dual GLP-1 and glucagon receptor agonist designed to balance appetite suppression with increased hepatic fatty-acid oxidation, reducing total fat mass and improving the lipid profile.
Mazdutide (IBI362 / LY3305677) is a synthetic dual peptide agonist and mimetic of the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR), structurally derived and modified from the human hormone oxyntomodulin. The peptide has an optimised amino-acid sequence conjugated to a C20 fatty diacid side chain through a specific linker, giving it reversible binding to serum albumin and extending its circulating half-life to allow a once-weekly subcutaneous dose. Mazdutide works through two complementary, simultaneous mechanisms: its GLP-1R arm acts on the central nervous system and the satiety centres of the hypothalamus and nucleus of the solitary tract to suppress appetite, delay gastric emptying and enhance glucose-dependent insulin release while restraining random glucose output from the liver; its GCGR arm acts on liver cells and brown adipose tissue to stimulate metabolic energy expenditure, increase hepatic fatty-acid oxidation and activate thermogenesis. This dual synergy sharply reduces total fat mass, lowers liver fat and treats metabolic fatty liver disease (MASLD/MASH), and improves blood pressure, triglycerides and cardiometabolic markers.
The dual GLP-1 and glucagon agonist for deep weight loss, liver-fat burning and a higher metabolic rate
If you are looking for the latest advance in metabolic medicine to overcome the limits of classic weight-loss drugs — achieving strong weight loss while speeding calorie burning and addressing stubborn liver fat at its roots — Mazdutide is the newest and most comprehensive generation of multi-target metabolic peptides.
Classification: Dual receptor agonists (GLP-1 / glucagon), regulators of appetite and energy expenditure, and treatments for obesity and metabolic fatty liver (Incretin-Glucagon Dual Agonists / Obesity & Metabolic Therapeutics).
Structurally, it is an advanced peptide inspired by natural oxyntomodulin and reinforced with a long fatty side chain. This gives it outstanding chemical stability and resistance to DPP-4, ensuring stable, extended metabolic activity throughout the week from a single light dose.
Picture your metabolic engine needing two simultaneous adjustments to run with exceptional efficiency: reducing the incoming fuel to prevent surplus (appetite suppression and slower digestion), and generating extra heat in the furnaces to burn old stored fuel (burning liver and adipose fat). Mazdutide handles both tasks at the same time without conflict.
How it works
Mazdutide circulates in the bloodstream and works through two complementary pathways in remarkable harmony. On the first, it binds GLP-1 receptors in the brain, pancreas and gut, sending strong, long-lasting fullness signals, slowing gastric emptying and regulating insulin release to keep post-meal blood sugar stable. On the second, distinct pathway, it activates glucagon receptors in liver tissue and fat cells, instructing the liver to break down its accumulated fat and convert it into heat energy — raising the body's basal metabolic rate even at rest. This unique dual effect not only lowers total weight by exceptional amounts but also removes deep visceral fat, lowers inflamed liver enzymes and improves LDL cholesterol, triglycerides and insulin resistance, offering comprehensive cardiac and metabolic protection beyond single-target drugs.
In advanced clinical and research settings, Mazdutide has achieved striking results in late-stage clinical trials for severe obesity, type 2 diabetes and metabolic-dysfunction-associated fatty liver disease (MASH/MASLD), and is seen as one of the strongest new contenders in weight management and metabolic health worldwide.
Overcoming obesity and visceral fat build-up no longer depends on food restriction alone — it rests on reprogramming the liver's fat-burning furnaces and controlling the neural satiety pathways together with high biological precision.
The newest dual agonist for satiety pathways and exceptionally efficient liver-fat burning. Mazdutide is a revolutionary medical achievement in obesity and metabolic-disease research, based on mimicking the body's dual balancing hormones. It belongs to the class of dual GLP-1 and glucagon receptor agonists that regulate appetite, multiply fat-burning rates and treat fatty liver. Its innovative structure activates two complementary satiety and burning pathways at once: it curbs excessive appetite and slows gut movement for lasting fullness, while awakening glucagon receptors in the liver to stimulate calorie burning and dissolve fat accumulated around vital organs. Its superior mechanism achieves marked, deep weight loss and restores clean liver cells, while improving insulin sensitivity and regulating blood lipids and blood pressure with long-acting safety. Leading metabolic and endocrine physicians follow it as the latest qualitative leap in reshaping the body's biological health and protecting it from the complications of obesity — because true metabolic transformation begins by tuning satiety signals and firing up the body's burning furnaces in complete harmony.
